Attenuation ob rubella virus by serial passage in primary rabbit kidney cell cultures. I. Growth characteristics in vitro and production of experimental vaccines at different passage levels

[The life cycle of Rubella Virus]

Rubella virus (RV), an infectious agent of rubella, is the sole member of the genus Rubivirus in the family of Togaviridae. RV has a positive-stranded sense RNA as a genome. A natural host of RV is limited to human, and rubella is considered to be a childhood disease in general. When woman is infected with RV during early pregnancy, her fetus may develop severe birth defects known as congenital rubella syndrome. In this review, the RV life cycle from the virus entry to budding is illustrated in comparison with those of member viruses of the genus alphavirus in the same family. The multiple functions of the RV capsid protein are also introduced.

Time-course induction of apoptosis by wild-type and attenuated strains of rubella virus

The time-course of rubella virus (RV)-induced apoptosis was studied in RK13 cells. DEVD-specific caspase activity assay and Western blotting for caspase-3 were used to determine the time-course of caspase activation and demonstrated that RV-induced apoptotic changes occur as early as 12 h post-infection (p.i.). Caspase activity followed a cyclic pattern, as seen with apoptotic-inducing drugs, with maximum activity detected at 72 h p.i. Apoptosis caused by wild-type (RN) and attenuated vaccine (Cendehill) strains of RV was compared by TUNEL staining, counting dead floating cells and DNA fragmentation analysis. Although the amount of apoptosis due to the wild-type strain was marginally greater, this was probably due to its faster growth rate.

Improved potency assay of rubella vaccine: parameters for plaque formation

Parameters for plaque formation by rubella vaccine strains licensed in Japan were studied. Formation of clear and large plaques on RK13 cells depends on several essential parameters. Plaques differed in morphology among five vaccine strains and the distinctiveness of the plaques was affected by pH of the agar overlay medium during incubation at 35 degrees C. Plaques became progressively larger in size as the concentration of sodium bicarbonate in the agar overlay medium increased from 0.04% to 0.15%, but the contrast of plaques to the background cells decreased markedly. The most distinct plaques of all vaccine strains were formed in the agar overlay medium containing 0.07% of sodium bicarbonate, i.e., pH 6.83, incubated in a humidified atmosphere containing 5% CO2. The number of plaques formed by vaccine strains decreased at 37 degrees C. Vaccine strains other than MEQ11 and TCRB19 formed larger and more contrasted plaques with sharp outline at 35 degrees C than at 32 degrees C. MEQ11 and TCRB19 strains yielded higher infective virus titres at 32 degrees C, but they formed distinct plaques at 35 degrees C and 32 degrees C. For the plaque test, the inoculum volume was another critical factor for obtaining an approximate titre that reflected the absolute titre of the sample. A volume of 0.1 ml was feasible for a well with a diameter of 35 mm.

Rubella vaccines: past, present and future

The association between rubella in pregnancy and congenital anomalies was first reported 50 years ago, by N. McAlister Gregg, an Australian ophthalmologist [1]. During the next 20 years his findings were confirmed by others (reviewed in [2]). However, the first reports of the isolation of rubella virus in cell cultures and development of tests for neutralizing antibodies were not published until 1962 [3, 4]. Subsequent studies conducted in the UK and North America during a pandemic of rubella in 1963–4, were therefore able to make a more accurate estimate of the risks of maternal rubella at different stages of pregnancy. It was estimated that about 30000 rubella-damaged babies were born in the USA alone in 1963–4 [5]. This emphasized the importance of developing a vaccine to prevent infection in pregnancy and thereby, the birth of babies with rubella-induced congenital defects.

Vaccines produced by conventional means to control major infectious diseases of man and animals

This chapter reviews the development of some of vaccines and their use in controlling such major diseases as diphtheria, rinderpest, Newcastle disease, smallpox, pertussis, yellow fever, rabies, etc. Park–Williams Number 8 (PW8) strain is used to make diphtherial toxoid for vaccines. As a source of toxin, it is rendered nontoxic by incubation with formalin under alkaline conditions. The product's retention of antigenicity, enabling it to induce antitoxin antibodies, makes it an excellent pediatric vaccine. Vaccine against Rinderpest Virus was developed by Koch in 1897 by administering bile from infected cattle. Animals that survived were permanently immune. Formalin- and chloroform-inactivated vaccines were developed using tissues from the infected animals. For the control of Newcastle disease, a number of attenuated live-virus vaccines have been developed which are widely used to control the disease. The Bl strain, the LaSota strain, and the F strain are used to immunize birds of all ages by different routes, including by addition to drinking water and by spraying. Protection against rabies correlates with SN antibody, which can be assessed by a number of tests. Pasteur's classical vaccine, developed from infected spinal cord tissue dried at room temperature for 3–14 days, was given in a series of 21–28 inoculations beginning with material dried the longest and progressing through material dried for only 3 days.

Markers of rubella virus strains in RK13 cell culture

When tested on RK(13) cell cultures, strains of rubella virus could be differentiated by their ability to form small or large plaques. Large plaques were produced by the HPV-77 and Cendehill strains, and also by a laboratory stock strain (West Point), after only 14 passages in RK(13) culture. Five wild-type rubella viruses, isolated and passaged only a few times in African green monkey kidney tissue culture, grew well in RK(13) cell culture, but they were sensitive to agar inhibitors and, therefore, formed small plaques. On the other hand, RA27/3, an attenuated strain grown in WI-38 human fibroblast cells, developed low titers in RK(13) cells and also produced small plaques. We concluded that the morphological differences between small-plaque and large-plaque viruses depended on their sensitivity to agar inhibitors and on the pH of the medium during plaque formation.